Evidence map›Paper›PMID 39580497›Full record

ArticleScientific data2024

A multi-region single nucleus transcriptomic atlas of Parkinson's disease.

Prashant N M, John F Fullard, Tereza Clarence, Deepika Mathur, Clara Casey, Evelyn Hennigan, Marcela Alvia, Joana Krause-Massaguer, Ayled Barreda, David A Davis and 15 more

Abstract readDataset
In one paragraph

Article in Scientific data, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Depletion of CD169Frontiers in neuroscience · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Prashant N M *Center for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-3548-5637
John F Fullard *Center for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0001-9874-2907
Tereza ClarenceCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-0099-2797
Deepika MathurCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Clara CaseyCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Evelyn HenniganCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Marcela AlviaCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Joana Krause-MassaguerCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ayled BarredaBrain Endowment Bank, Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA.
David A DavisBrain Endowment Bank, Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0002-9323-6180
Regina T VontellBrain Endowment Bank, Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA.
Susanna P GaramszegiBrain Endowment Bank, Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA.
Jeffery M VanceJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA.
Lorelle SangMcLean Hospital, Belmont, MA, USA.
Michael ChatignyMcLean Hospital, Belmont, MA, USA.
David VismerTechnome LLC, Herndon, VA, USA.
Barry LandinTechnome LLC, Herndon, VA, USA.
David BursteinCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Donghoon LeeCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-0453-6059
Georgios VoloudakisCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-5729-632X
Sabina BerrettaMcLean Hospital, Belmont, MA, USA.
Vahram HaroutunianFriedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0001-5860-2512
William K ScottBrain Endowment Bank, Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0001-9336-6404
Jaroslav BendlCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA. jaroslav.bendl@mssm.edu.
Panos RoussosCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA. panagiotis.roussos@mssm.edu.ORCID 0000-0002-4640-6239

Funding

Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4M
THE GENETICS OF PARKINSONISMP50NS039764 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI VANCE, JEFFERY MARVIN · 1999 to 2010
$15.6M
Vitamin D Concentration, Genetic Modifiers, and Parkinson DiseaseP50NS071674 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI VANCE, JEFFERY MARVIN · 2010 to 2015
$10.2M
Single-nucleus transcriptome profiling across multiple brain regions in Parkinson's DiseaseU01NS125580 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HAROUTUNIAN, VAHRAM, ROUSSOS, PANAGIOTIS · 2021 to 2021
$2.1M
COVID and Translational Science supercomputer (CATS)S10OD030463 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2021 to 2021
$2.0M
Big Omics Data Engine 2 SupercomputerS10OD026880 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2019 to 2019
$2.0M
NCATS NIH HHS UL1 TR004419NIH HHS S10 OD026880NIH HHS S10 OD030463NINDS NIH HHS P50 NS039764NINDS NIH HHS P50 NS071674NINDS NIH HHS U01 NS125580U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) U01NS125580
6 · The paper itself

Abstract

Parkinson's Disease (PD) is a debilitating neurodegenerative disorder, characterized by motor and cognitive impairments, that affects >1% of the population over the age of 60. The pathogenesis of PD is complex and remains largely unknown. Due to the cellular heterogeneity of the human brain and changes in cell type composition with disease progression, this complexity cannot be fully captured with bulk tissue studies. To address this, we generated single-nucleus RNA sequencing and whole-genome sequencing data from 100 postmortem cases and controls, carefully selected to represent the entire spectrum of PD neuropathological severity and diverse clinical symptoms. The single nucleus data were generated from five brain regions, capturing the subcortical and cortical spread of PD pathology. Rigorous preprocessing and quality control were applied to ensure data reliability. Committed to collaborative research and open science, this dataset is available on the AMP PD Knowledge Platform, offering researchers a valuable tool to explore the molecular bases of PD and accelerate advances in understanding and treating the disease.

Indexed as

Parkinson DiseaseTranscriptomeAgedBrainHumansSequence Analysis, RNA

Identifiers

PMID39580497
PMCPMC11585549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.